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INVESTIGATION
Caenorhabditis elegans DAF-2 as a Model for
Human Insulin Receptoropathies
David A. Bulger,*,†,1 Tetsunari Fukushige,* Sijung Yun,* Robert K. Semple,† John A. Hanover,‡,2
and Michael W. Krause*,2
*Laboratory of Molecular Biology and ‡Laboratory of Molecular and Cellular Biology, National Institute of Diabetes and
Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland 20878, and †Institute of Metabolic
Science, University of Cambridge, Cambridge, UK
ABSTRACT Human exome sequencing has dramatically increased the rate of identiﬁcation of disease-
associated polymorphisms. However, examining the functional consequences of those variants has created an
analytic bottleneck. Insulin-like signaling in Caenorhabditis elegans has long provided a model to assess
consequences of human insulin signaling mutations, but this has not been evaluated in the context of current
genetic tools. We have exploited strains derived from the Million Mutation Project (MMP) and gene editing to
explore further the evolutionary relationships and conservation between the human and C. elegans insulin
receptors. Of 40 MMP alleles analyzed in the C. elegans insulin-like receptor gene DAF-2, 35 exhibited insulin-
like signaling indistinguishable from wild-type animals, indicating tolerated mutations. Five MMP alleles proved
to be novel dauer-enhancing mutations, including one new allele in the previously uncharacterized C-terminus
of DAF-2. CRISPR-Cas9 genome editing was used to conﬁrm the phenotypic consequence of six of these DAF-2
mutations and to replicate an allelic series of known human disease mutations in a highly conserved tyrosine
kinase active site residue, demonstrating the utility of C. elegans for directly modeling human disease. Our
results illustrate the challenges associated with prediction of the phenotypic consequences of amino acid
substitutions, the value of assaying mutant isoform function in vivo, and how recently developed tools and
resources afford the opportunity to expand our understanding even of highly conserved regulatory modules
such as insulin signaling. This approach may prove generally useful for modeling phenotypic consequences
of candidate human pathogenic mutations in conserved signaling and developmental pathways.
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The evolutionarily conserved insulin/IGF-1 signaling (IIS) pathway is a
critical regulator of growth, development, and longevity (Taniguchi
et al. 2006). In humans, excess insulin signaling is associated with
overgrowth and cancer, while loss of signaling results in insulin re-
sistance and diabetes (Lindhurst et al. 2012). The recent expansion of
human polymorphisms identiﬁed in genes encoding insulin signaling
molecules is generating a potentially valuable resource for the diagnosis
of metabolic disease. Full understanding of the functional consequences
of these polymorphisms ideally requires models providing in vivo con-
text, that is, in which the complete developmental and metabolic pro-
gram is an integral part of the phenotype.
The nematode Caenorhabditis elegans has proven to be an ex-
cellent animal model in which to examine insulin-like signaling. In
C. elegans, reduction or partial loss of IIS has pleiotropic effects,
including altered stress responses and increased longevity (Gottlieb
and Ruvkun 1994). The worm IIS also controls entry into the dauer
stage under adverse conditions (e.g., overcrowding, elevated tem-
perature, and starvation), providing a convenient readout for the
strength of IIS signaling. Genetic screens for dauer formation de-
fective (Daf-d), and dauer formation constitutive (Daf-c), mutants
have identiﬁed alleles in C. elegans genes encoding each of the IIS
pathway components that have helped to deﬁne and understand this
important signaling cascade (Gottlieb and Ruvkun 1994; Malone
and Thomas 1994; Hu 2007).
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Forward genetic screens in C. elegans for Daf-d or Daf-c mutants,
and their suppressors, impose an inherent bias due to the selection for a
speciﬁc phenotype. It is unclear to what extent that bias has limited
genetic analysis of the IIS pathway. For example, the strong phenotypes
selected by such forward screens may miss those alleles that more
closely mimic human disease-associated polymorphisms that result
in more subtle metabolic phenotypes. One approach that minimizes
the possible bias of phenotypic selection is to isolate randommutations
in pathway components prior to assaying the mutant alleles for phe-
notypes. This approach also allows for the identiﬁcation of silent mu-
tations that provide information on tolerated alleles in pathway
components. The Million Mutation Project (MMP) in C. elegans pro-
vides such a resource, consisting of a distributed collection of genetic
alleles generated by chemical mutagenesis and selected only for viability
at room temperature (Thompson et al. 2013). Each MMP strain has
been clonally selected and expanded for ten generations followed by
whole genome sequencing, providing a rich array of nonlethal homo-
zygous variants within most genes of interest that are available for
further study.
Wehave taken advantage of theMMPresource to further investigate
IIS, focusing on novel alleles of the single insulin-like receptor in the
worm, DAF-2. The DAF-2 protein has already been extensively ana-
lyzed using the mutants obtained through genetic screens, which
resulted in a classiﬁcation of the daf-2mutants into Class I and pleio-
tropic Class II based on the constellation of phenotypes (Gems et al.
1998; Patel et al. 2008). Genetic screens have isolated several temperature-
sensitive, reduction-of-function alleles in daf-2, demonstrating that
reduced IIS activity results in animals entering the dauer stage under
conditions in which wild type animals would not. This well-deﬁned,
graded response makes DAF-2 an ideal candidate to test the value of
the MMP resource in providing additional insight into gene func-
tion. We have taken advantage of a very sensitive high tempera-
ture-induced dauer assay (Ailion and Thomas 2003) to screen
MMP alleles distributed throughout the daf-2 coding region
for dauer-related phenotypes. Of the 40 daf-2 MMP alleles we
analyzed, 35 retained IIS function and were indistinguishable
from wild-type animals, providing the ﬁrst list of tolerated sub-
stitutions. Importantly, ﬁve MMP alleles deﬁned novel dauer-
enhancing mutations. Using CRISPR-Cas9 genome editing, we
have conﬁrmed the phenotype for many of these alleles, and rep-
licated an allelic series of known human disease mutations in a
highly conserved tyrosine kinase active site residue. Our results
capitalize on existing MMP alleles to expand our understanding
of residues critical for DAF-2 function, while demonstrating the
usefulness of C. elegans genomics to model human alleles for func-
tional studies in the context of a developing and metabolically
active animal system.
MATERIALS AND METHODS
Nematode culture and strains
Strain construction: StandardC. elegansmaintenance procedureswere
followed (Brenner 1974). N2 (Bristol) wild-type and RW3625 let-805
(st456)/qC1 [dpy-19(e1259ts) glp-1(q339)] were used as negative con-
trols and for backcrossing. The following strains were obtained using
microinjection of the pDD162 plasmid-based CRISPR-Cas9 system
(Dickinson et al. 2013; Paix et al. 2014) with a coedited dpy-10(cn64)marker
(Arribere et al. 2014) (Supplemental Material, Table S4): daf-2(gv51[P155L]),
daf-2(gv52[S341P]), daf-2(gv53[A746T; del]), daf-2(gv54[A1015V]),
daf-2(gv55[A1391T]), daf-2(gv56[A1391V]), daf-2(gv57[A1391E]),
and daf-2(gv58[A1729V]).
Sequencing of mutant alleles
Note that all INSR and DAF-2 amino acid designations refer to the
preproreceptor sequence. All daf-2 exons were sequenced using nested
PCR followed by Sanger sequencing with 13 amplicons used to cover
the entire coding region (Table S1). For strains with previously identiﬁed
mutations, only the relevant exon was sequenced; MMP allele sequences
were available from both the WormBase (http://www.wormbase.org/)
and MMP (http://genome.sfu.ca/mmp/) websites. Strains were con-
tinuously veriﬁed after genetic crosses and propagation using Sanger
sequencing of the affected exon region.
Two daf-2mutants, sa753 and sa875, isolated previously in a high-
temperature dauer positive selection screen (Ailion and Thomas 2003),
were found by whole gene sequencing of daf-2 to have the same DAF-2
(P470L) substitution, which has been previously reported as one of the
two mutations found in mg43, DAF-2(C401Y; P470L) (Kimura et al.
1997).
High-temperature dauer assay
Gravid adults (1–10) were grown at 20 and allowed to lay embryos
overnight (12 hr), the adults were removed and the plates were shifted
to either high temperature (27.2) or a range of typical incubation
temperatures (15, 20, and 25) (Ailion and Thomas 2003). After
72 hr at the assay temperature, the progeny were scored by counting
the number of dauers, early larval stage animals, and adults on each
plate. Worms that had crawled up the edge of the plate were also
counted (Lee et al. 2011). Some high temperature dauer plates were
left at 27.2 for another 72 hr, and then recovered at 15 for 7 d. These
plates were then scored for having sterile adults with dead progeny
(wild-type), dauers that recovered as fertile adults, or live dauers that
remained arrested.
Molecular dynamics simulation
Molecular dynamics simulationswere performed usingNAMDversion
2.9 on the human INSR tyrosine kinase (PDB: 4XLV) and its point
mutation variants. The point mutations were induced using PyMol
Molecular Graphics System, Version 1.7.6.0 Schrödinger, LLC.
CHARMM Version 27 force ﬁeld parameters were used to generate
solvated psf ﬁles with a 15 Å additional layer of water molecules from
themost outer portion of the protein (Brooks et al. 2009). The time step
of the simulation was 1 fs. Periodic boundary condition was used. For
equilibration, 5000 steps of energy minimization with conjugate gradi-
ent method has been performed initially, then the temperature was
raised from absolute zero to 37 in 1 intervals using Langevin dynamics,
with 1 ps of simulation at the temperature. Then, ﬁve cycles of 10 ps
simulation with 2000 steps of energy minimization were performed.
Each simulationwas performed for an additional 20 ns (videos provided
in File S2, File S3, File S4, and File S5).
Data availability
Strains are available upon request. Table S1 contains primers used for
daf-2 sequencing. Table S2 contains a complete list of the dauer assay
results by independent isolate. Table S3 contains dauer-associated
mutations in prebackcrossedMMPstrains. Table S4 contains theCRISPR-
Cas9 gRNA and dsDNA repair template sequences with associ-
ated protocols. Table S5 contains SIFT, Polyphen2, AlignGVGD,
and PROVEAN results. Table S6 contains quality scores and metrics
for the DAF-2 I-TASSER model (Figure 4). Table S7 contains PDB
IDs with supporting data for the human tyrosine kinase structural
analysis. Figure S1 contains the human-to-worm sequence alignment
annotated with the MMP mutations. File S1 contains the complete
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sequence alignment ﬁle. File S2, File S3, File S4, and File S5 contain
molecular dynamics simulations highlighting the ATP movements in
the tyrosine kinase binding pocket of normal and mutant human
INSR. High resolution videos are available upon request. File S6 con-
tains the human tyrosine kinase active site alignment. File S7, File S8,
File S9, File S10, File S11, File S12, and File S13 contain the DAF-2
I-TASSER model PDB ﬁles (Figure 4).
RESULTS
Recent advances in worm genetics and genomics have accelerated the
ability to generate, map, and characterize mutant alleles. We devised a
pipeline to examine the extent to which these technological advances
could be applied to a well-characterized and evolutionarily conserved
pathway to both gain a deeper understanding of structure-function
relationships and to model human disease. The insulin-like signaling
pathway was chosen for a detailed analysis. As shown in Figure 1, this
pipeline was designed to use information derived from existing muta-
tions in the human IIS as a starting point and to use C. elegans genetics
to model mutations in conserved regions of components of this well-
studied pathway. The strategy used bioinformatic tools coupled with
allele selection and gene editing to examine a robust insulin-dependent
phenotype in an intact organism, focusing on a high-throughput dauer
assay.
DAF-2 MMP alleles as a proof-of-principle target
Alleles available from the MMP were selected solely on the basis of
survival at room temperature (Thompson et al. 2013). One goal of
this study was to determine if MMP alleles would have value in
further understanding the IIS pathway. In humans, defects in in-
sulin signaling can present with a wide range of phenotypic conse-
quences for the affected patient. Modeling this phenotypic spectrum
may require the identiﬁcation of more subtle phenotypes than tra-
ditional screens allow.
To fully understand the scope of IIS pathwaymutants available in
C. elegans, we interrogated WormBase (v245) for all known alleles
in evolutionarily conserved IIS pathway genes (Howe et al. 2016),
including genetic mutants, deletion alleles, and nonsynonymous
single nucleotide polymorphisms (nsSNPs) identiﬁed by the
MMP. As Figure 2A demonstrates, the MMP nsSNPs greatly expand
the range of mutations available for the components of the IIS
pathway. We focused this study on the sole C. elegans insulin-like
receptor, DAF-2, for several reasons: (1) 40 new missense alleles
were present in the MMP collection, allowing us to further assess
DAF-2 structure-function; (2) reduction of DAF-2 activity results in
an easily scored dauer phenotype in a dose-dependent manner; (3)
25 mutants resulting in a dauer, or more severe larval arrest, phe-
notype with a known genotype have previously been characterized;
and (4) the protein is closely related to the human insulin receptor
(INSR), which has been extensively characterized in patients with
severe insulin resistance, and morbidity due to INSR mutations
(Gems et al. 1998; Patel et al. 2008).
The available daf-2MMP nsSNP alleles were distributed across the
entire gene locus, with hits affecting exons encoding all major domains
of the protein (Figure 3 and Figure 4). There was an average of
8.7 MMP mutations per kilobase in daf-2 with hit frequencies similar
in exons (10/kb) and introns (8.4/kb); a similar distribution was ob-
served across other IIS pathway genes (Thompson et al. 2013). Com-
plete loss of daf-2 function results in embryonic lethality or early larval
arrest (Gems et al. 1998); thus, none of the MMP alleles would be
expected to be null on their own. It is possible that homozygous
daf-2 lethal alleles could be among theMMPcollection due to coselection
for second site suppressors of the lethality. Previous work has shown
mutations in DAF-18/PTEN can act as such a suppressor (Ogg
and Ruvkun 1998). In fact, three daf-2 MMP strains we selected
(VC40071, VC41001, and VC40691) also had nsSNPs in daf-18,
which might allow the strains to survive the MMP room-temperature
viability requirement, even with a loss-of-function daf-2 mutation
(Table S3). This highlights the value of the complete genome se-
quence, and the need to genetically outcross these strains prior to
further study (see below, and Materials and Methods).
To determine the distribution of nsSNP alleles among evolutionarily
conserved and nonconserved domains of DAF-2, we aligned related
protein sequences both from within and between genera (File S1 and
Figure S1). Six Caenorhabditid species with sequenced genomes were
included in this analysis:C. elegans,C. remanei,C. briggsae,C. brenneri,
C. sp5, andC. tropicalis.We also included genera that hadwell-annotated
genomic, transcriptomic, and proteomic evidence for an insulin-like
receptor (human, chimp, mouse, rat, frog, zebraﬁsh, and ﬂy). In order
to correct for variable-sized insertions and deletions of nonconserved
amino acids in DAF-2 relative to related receptors, T-COFFEE
Figure 1 Strategy and analysis pipeline exploiting human insulin-
receptoropathy-associated polymorphisms and linking them to emerg-
ing C. elegans genetic tools. Among the components of the insulin
signaling pathway, the human insulin receptor was chosen for its high
degree of sequence similarity with C. elegans DAF-2. A combination
of existing dauer mutants (Daf-defective and Daf-constitutive), MMP
alleles and CRISPR-Cas9 generated alleles were coupled with a recur-
sive veriﬁcation of a high-temperature induction of dauer (Hid) pheno-
type to provide a detailed look at conserved regions of the human
insulin receptor and the functional consequences of conservative and
nonconservative replacements of critical residues in the tyrosine kinase
domain.
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multiple-sequence alignments were performed with anchors at known
functional sequence motifs surrounding clearly identiﬁable domains,
including the insulin binding domain, ﬁbronectin type III repeats,
trans-membrane domain, and kinase domain (Morgenstern et al.
2006; Taly et al. 2011). This approach gave improved sequence align-
ments that allowed us to determine the degree of amino acid conser-
vation both between andwithin genera (Figure S1, File S1, andTable 1).
As expected, the majority of MMP nsSNPs (28/40) were located in
regions that were not evolutionarily conserved, in contrast to previous
phenotypic screens that isolated mutations only in highly conserved
domains of the DAF-2 receptor (Figure 2B). Among those SNPs in
highly conserved domains, we found four altered residues that were
identical when comparing human and C. elegans insulin receptors.
These four allowed us to applymultiple algorithms, including PolyPhen2,
SIFT, Align GVGD, and PROVEAN (Table S5), to predict the potential
functional consequences of these substitutions (Kumar et al. 2009;
Adzhubei et al. 2010; Hicks et al. 2011; Choi et al. 2012). Each of these
four mutants, two within the insulin binding domain [(DAF-2(P470L),
DAF-2(A508T)) and two within the tyrosine kinase domain
(DAF-2(E1380K), DAF-2(A1391T)], was predicted by multiple analytic
programs to be deleterious, suggesting they should result in a pheno-
type. For the remaining eight MMP alleles, which altered conserved
nonidentical residues, the anchored sequence alignment and functional
motif requirements of each domain were assessed. Three of these mu-
tants [DAF-2(V653M), DAF-2(A906V), andDAF-2(L1189F)] were pre-
dicted not to affect function, because the missense mutation retained
conserved hydrophobicity at the residue position (Table 1 and Table 2;
asterisks). Similarly, three mutants [DAF-2(P155L), DAF-2(S341P), and
DAF-2(A746T)] resulted in moderately conservative substitutions that
might not be expected to affect function (Table 1; daggers). We con-
cluded that the MMP daf-2 allele collection provided a useful mix of
amino acid substitutions, including several changes in conserved residues
that had a high likelihood of affecting function and, therefore, would
likely have a dauer-related phenotype.
Multiple MMP daf-2 alleles have a high temperature
induction of dauer (Hid) phenotype
The large burdenofmutations in the originalMMPstrains, visible in the
genomic sequencedata, often resulted in poor growth andhigh lethality;
thenumber of nsSNPsper strain for the 40daf-2allele-containing strains
studied ranged from 198 to 1025 (mean 6 SD of 471.6 6 187). Two
genetic backcrosses were performed for each MMP strain using a genetic
marker for the daf-2 region {let-805st456/qC1 [dpy-19(e1259) glp-1(q339)]},
and at least two independent outcrossed isolates were selected for
Figure 2 The evolutionarily conserved
insulin-like signaling pathway mem-
bers, associated alleles, and their dis-
tributions. (A) The C. elegans and
human insulin signaling pathways are
highly conserved from the DAF-2/INSR
insulin-like receptor all the way to the
DAF-16/FOXO nuclear transcription fac-
tor [pathway adapted from Christensen
et al. (2002)]. Only the pathway proteins
associated with human insulin resistance
and/or C. elegans dauer phenotypes are
shown in this simpliﬁed diagram. Dauer-
associated alleles identiﬁed in previous
genetic screens are indicted in red and
gray bars labeled “Missense” and “Other,”
respectively. MMP alleles are shown by
blue bars. (B) Distinct distributions of phe-
notypically selected vs.MMP DAF-2 alleles
among conserved and nonconserved
residues. DAF-2 alleles identiﬁed by
phenotypic selection appear to be biased
toward substitutions in evolutionarily con-
served residues, as deﬁned in Table 1. In
contrast, MMP alleles that were selected
only for viability at room temperature do
not seem to exhibit this bias.
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each allele. The independent outcrossed isolates allowed us to control
for the inﬂuence of residual background mutations in our assays, a
potential confounding factor given some strains had up to four
additional mutations in genes known to affect dauer formation
(Table S3). With a few exceptions (Table S2), none of the indepen-
dent isolates after backcrossing had noticeable phenotypes at room
temperature.
We screened each of the outcrossed MMP allele isolates for DAF-2
function by scoring for a high temperature induction of dauer (Hid)
phenotype. High-temperature (27.2) has previously been shown to
induce dauers at low frequency in wild-type animals, and to enhance
the dauer phenotype of weak DAF-2 loss-of-function alleles (Ailion
and Thomas 2003). We also assayed two additional strains (CB120
and JT6) that were previously identiﬁed in genetic screens for consti-
tutive dauers (Daf-c), but for which the molecular lesion was unknown;
sequencing the daf-2 locus in each strain allowed us to identify the
causative mutation (see below).
Of the 42 strains harboring nsSNPs assayed for a Hid phenotype at
27.2, four strains had a clear dauer phenotype (.80% dauer with
SE ,15), six strains had a variable dauer phenotype, and 32 strains
had no observable dauer phenotype (,3.5% dauer with SE ,2.5)
(Table 1). All four strains resulting in a clear dauer phenotype had mu-
tations in the insulin binding domain (amino acid residues 140–774). Two
of these were novel MMP strains [DAF-2(R375C) and DAF-2(A746T)],
and two were previously identiﬁed strains (CB120 and JT6), in which
we identiﬁed the same DAF-2(P470L) mutation. Two of these three
Hid-associated substitutions affected highly conserved amino acid
residues. Alanine746 was conserved between 22 of the 27 receptors
we aligned, with only 5/11 Drosophila species having a serine instead
Figure 4 Novel DAF-2 structural model highlighting known mutations
including newly characterized MMP alleles and their phenotypic
consequences. A structural model of the DAF-2 insulin-like receptor
is shown as a monomer based on domain-by-domain modeling using
the online I-TASSER server (http://zhanglab.ccmb.med.umich.edu/
I-TASSER/) and I-TASSER 2.1 (File S7, File S8, File S9, File S10, File
S11, File S12, File S13, and Table S6) (Zhang 2008). Missense and
nonsense mutations from phenotypic screens and MMP mutations
are shown as indicated in the legend. The domain labels have been
color-coded to correspond to the protein domains in Figure 3. The
predicted signal peptide sequence is represented by an N-terminal
dotted line with the cleavage site indicated at residue 143 (scissors).
The position and number of Fibronectin Type III-like domains is un-
certain due to an additional 75 amino acids that are present in DAF-2
when compared to human INSR (Figure 5). The putative furin-like
cleavage site is at residue 930 (scissors). The receptor alpha and beta
strands resulting from furin cleavage are each labeled at their N- and
C-terminal ends (N-a, C-a, N-b, and C-b). The position and residue
changes of MMP alleles resulting in a dauer phenotype are highlighted
with black arrows and text. Only MMP mutations with a dauer pheno-
type and the three CRISPR-Cas9 mutations at A1391 are identiﬁed.
Residue numbering refers to the preproreceptor. This method of
displaying mutations was adapted from (Patel et al. 2008); the struc-
ture shown is a novel model of DAF-2 based on I-TASSER structural
modeling.
Figure 3 Distribution of the position of phenotypic and MMP alleles in
the exons and protein domains of DAF-2. The C. elegans daf-2 exons
(introns have been excluded) are shown at left in black and gray, with
the corresponding protein domains in color on the right. Schematic
style adapted from De Meyts and Whittaker (2002). Mutations from
previous phenotypic screens can be seen, with missense mutations in
red and nonsense mutations in black; MMP alleles can be seen in blue
on the right. Asterisks indicate which of the MMP alleles were found to
have novel dauer phenotypes in this study. While the exons and pro-
tein domains are shown to scale, the positions of the lines indicating
individual mutations are approximate.
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n Table 1 Conservation and phenotypic consequences of novel DAF-2 mutations
For each allele, the genotype, residue change (Change), degree of conservation (Cons), amino acid property change (Effect), and predicted phenotypic effect
(Prediction) are indicated. In addition, high-temperature induction of dauer (Hid) phenotype, percent dauer (%D), standard deviation (STDEV), standard error (SE),
number of worms assayed (N), and number of independent isolates (I.I.) are shown. Residue numbering refers to the preproreceptor.
Colors are shown as deﬁned in Figure 3. WT, Wild Type; I., identical; Ch. Rev., charge reversal.
a
Substituting residue is found at the corresponding location in a human insulin-like receptor.
b
Substituting residue maintains conserved amino acid charge.
c
Identical residue found in 22/27 aligned sequences (File S1).
d
Conserved charge change.
e
Substituting residue maintains hydrophobicity of the transmembrane domain.
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of an alanine. Proline470, altered in strains CB120 and JT6, was conserved
in 25 of the 27 aligned species, with only the two Branchiostoma species
having a glutamate at that position. The less-conserved residue change
that also resulted in a clear dauer phenotype, DAF-2(R375C), was only
conserved in four out of the six aligned Caenorhabditids (C. elegans,
C. remanei, C. briggsae, and C. sp5), and 8/21 of the remaining aligned
species, with 10 of the other species having either a lysine or a proline at
this position. Thus, while strong evolutionary conservation of a residue
was a very good predictor for mutations resulting in mutant phenotypes,
substitutions in residues with weaker conservation also had functional
consequences.
The six strains with variable dauer phenotypes affected amino
acid residues dispersed across ﬁve different domains of the protein:
DAF-2(R10Q) in the signal peptide, DAF-2(P155L) and DAF-2(S341P)
in the insulin binding domain, DAF-2(A1015V) in the ﬁbronectin
type III domain, DAF-2(E1380K) in the tyrosine kinase domain, and
DAF-2(A1729V) in the C-terminal domain. The signal peptide mu-
tant, DAF-2(R10Q), was in a residue located after the ﬁrst SL1 trans-
splice site (Krause and Hirsh 1987), the major trans-spliced isoform,
which is part of a potential (but experimentally unconﬁrmed) RXRR
furin cleavage site. The remaining ﬁve variable Hid-associated strains
similarly affected residues with only moderate-to-low conservation,
weakening our conﬁdence in attributing the phenotype to the daf-2
nsSNP. The proline155 residue is conserved only among worms
(Caenorhabditids and Brugia) with nonpolar amino acids (L, I, V, A)
in the other aligned higher eukaryotes. Because leucine is found at this
position in higher eukaryotes, theMMPDAF-2(P155L) mutation was
not expected to yield a dauer phenotype. The other insulin binding
domain substitution [DAF-2(S341P)] affected a serine conserved only in
the two alignedXenopus species, with higher eukaryotes (mouse, rat, chimp,
and man) having a threonine at that position. The DAF-2(A1015V)
substitution is in a residue that is neither conserved among worms nor
the other aligned organisms. The DAF-2(E1380K) substitution affects
a tyrosine kinase glutamate residue that is conserved only among
Caenorhabditids, at the same site as the glutamine thought to anchor
the E-helix to the F-helix in the human INSR. Finally, theDAF-2(A1729V)
change had a weak dauer phenotype with a standard deviation greater
than the mean percentage of dauers (12.9 6 18.7%). This residue is
only conserved among Caenorhabditids, and this region of the C-terminal
domain is unique to this genus. Based on relatively weak sequence
conservation of affected residues, we concluded that, with these re-
sults alone, we could not conﬁrm that any of these substitutions cause
the weak and variable dauer phenotypes.
The 32 MMP alleles that were indistinguishable from wild-type
controls in our Hid phenotype assay were mostly in nonconserved
residues distributed across the protein with two clear exceptions:
DAF-2(A508T) in the insulin binding domain, and DAF-2(A1391T)
in the tyrosine kinase domain. DAF-2(A1391T) was especially surpris-
ing since it was in a conserved catalytic loop amino acid residue found
to be mutated in several patients with severe insulin resistance (Cama
et al. 1993; Moreira et al. 2010). This mutation will be discussed below
in the context of our results from CRISPR-Cas9 genome edited strains.
Validating dauer phenotypes by CRISPR-Cas9
genome editing
To validate dauer phenotypes observed in the outcrossed strains, we
carried out genome edits to mimic daf-2 MMP alleles in an otherwise
isogenic, wild-type genetic background using a dpy-10 coediting strat-
egy (Arribere et al. 2014). Genome editing using the CRISPR-Cas9
system has become robust for many, but not all, target sites in the
C. elegans genome (Paix et al. 2014). We initially selected DAF-2 alter-
ations R10Q, P155L, S341P, A746T, A1015V, E1380K, and A1729V for
validation; we were successful in generating at least two independent
strains with precise edits for all of these except R10Q and E1380K
(Table S4).
Strains harboring the successfully CRISPR-Cas9 edited alleles were
each assayed for a Hid phenotype, and the results compared to our
genetic alleles (Table 2). As expected, the edited allele generating the
insulin binding domain alteration A746T had a strong dauer pheno-
type, matching the MMP genetic results for this substitution. Two
genomic edits resulting in substitutions (A1015V and A1729V) had
moderate Hid phenotypes, also consistent with the MMP genetic al-
leles. Interestingly, the A1729V substitution had a consistently low
percentage of dauer formation in both the MMP outcrossed strains
(12.9%), and CRISPR-Cas9 edited strains (7.4%); we concluded this
amino acid substitution was causative. This is the ﬁrst dauer-enhancing
allele identiﬁed in the DAF-2 C-terminal domain about which little is
known functionally. Finally, two DAF-2 substitutions (P155L and
S341P) had no Hid phenotype, in contrast to our genetic results. Thus,
analysis of CRISPR-Cas9 edited alleles was essential in validating which
of the MMP substitutions were causative for the dauer phenotype.
Based on this analysis, seven of the assayed strains (ﬁve MMP,
CB120, JT6) were validated as true Hid positives, while 35MMP alleles
resulted in a phenotype indistinguishable from wild type in the high
temperature-induced dauer assay.
n Table 2 Validation of MMP phenotypes and modeling of conserved human disease alleles by CRISPR-Cas9
The domains, residue changes, conservation, dauer phenotype, and associated statistics for each of the engineered alleles are given. Residue numbering refers to the
preproreceptor. Vertical colored bars reﬂecting different protein domains are consistent throughout tables and ﬁgures as deﬁned in Figure 3. Dauer, number of dauer
larvae; EL, number of embryonic lethal; Binding, ligand binding; FnIII, ﬁbronectin Type III; Tyr K, tyrosine kinase; C-term, C-terminal.
a
Substituting residue is found at the corresponding location in a human insulin-like receptor.
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C. elegans DAF-2 mutations faithfully model human
disease alleles
Of the human INSRmutations associated with disease, ﬁve correspond
to conserved residues in DAF-2 for which mutations have previously
been identiﬁed that affect dauer formation (Table 3). A single MMP
mutation [DAF-2(A1391T)] we assayed matched a known human
INSR allele, but, surprisingly, resulted in no observable Hid phenotype.
This DAF-2 variant aligned with both the INSR(A1135E) mutation
found in a patient with Type A Insulin Resistance, and the compound
heterozygous INSR(A1135V; N878S) mutation found in a patient with
Rabson-Mendenhall Syndrome, a very severe form of insulin resis-
tance. The lack of a Hid phenotype in this strain suggested that the
C. elegans threonine substitution was tolerated despite the bioinfor-
matic predictions to the contrary. This residue was chosen for further
study to determine if mimicking the human disease alleles in C. elegans
would provide additional insight.
We generated three alanine1391 substitutions in C. elegans DAF-2
using CRISPR-Cas9 genomic editing, and assayed each for a Hid phe-
notype. One change [DAF-2(A1391T)] replicated the MMP allele that
had no Hid phenotype. The other two changes [DAF-2(A1391V) and
(A1391E)] mimicked human INSR substitutions resulting in disease.
The DAF-2(A1391T) edited strains had no observable dauer pheno-
type, reproducing the results from the corresponding MMP strain,
conﬁrming that this substitution is tolerated in DAF-2. In contrast,
the two other human disease substitution mimics had Hid phenotypes,
although both the severity and penetrance of the phenotype differed
between them. The DAF-2(A1391V) mutation resulted in 98.7%
dauers at 27.2 and 0% dauer at 20. Interestingly, the DAF-2(A1391E)
edit could only be maintained as a heterozygote; animals harboring
this edit gave rise to 25% dauer progeny at 15, 20, and 25, suggesting
the homozygous mutation had a Daf-c phenotype (Table 4). We
conﬁrmed this by genotyping individual progeny of these putative
heterozygous animals, and found that 10 out of 10 sequenced indi-
vidual dauer progeny were homozygous for the mutation and none of
30 sequenced nondauer progeny were homozygous for the mutation
(only wild type, or heterozygous). Thus, the DAF-2(A1391E) homo-
zygotes were found to be constitutive dauer at all temperatures tested,
mimicking the severe phenotype observed in humans heterozygous
for this same substitution. Importantly, our DAF-2 edits generated an
allelic series for variants at this residue that were consistent with human
disease severity: A1135T (tolerated), A1135V (moderate defect), and
A1135E (severe defect).
We explored these daf-2 alanine1391 substitutions in more detail to
understand the molecular basis of the lesions. Alanine1391 is located at
the center of the tyrosine kinase active site, and is highly conserved.
Sequence alignment between the HRD and DFGmotifs, which deﬁne a
key 23 amino acid long region of the tyrosine kinase active site
(Wheeler and Yarden 2015), demonstrated that an alanine is found
in 79 out of the 90human tyrosine kinaseswe aligned; nine of 90 human
tyrosine kinases have a threonine at this site, and only one (FAK2) has a
valine (a possible loss-of-function variant) (File S6). Thus, like our
in vivo results in C. elegans, sequence alignments suggest threonine
may be a tolerated substitution at this position in humans.
To further understand the molecular consequences of substitutions
at human INSR alanine1135 (corresponding to DAF-2 alanine1391), we
turned to available structural data. Due to the numerous human dis-
eases caused by tyrosine kinase dysfunction, several human tyrosine
kinase crystal structures were available to explore the potential conse-
quences of substitutions at this site (Berman et al. 2002). In the crystal
structures for seven of the nine human tyrosine kinases with a
threonine at this position, the threonine is stabilized through a
hydrogen bond with a nearby glutamate (Table S7). To see if this
might also be the case for the human INSR(A1135T) variant,
CHARMMmolecular dynamics simulation with periodic water sol-
vation was performed for 20 ns on the human INSR tyrosine kinase
crystal structure with the wild-type alanine, or an identical sequence
with that residue substituted with a threonine (videos in File S5). We
found that the wild type and A1135T variant INSR simulations
resulted in no signiﬁcant changes in the stability of the tyrosine
kinase domain and active site conﬁguration. We extended this anal-
ysis to determine the potential effects of the valine and glutamate
substitutions at this residue that are associated with human disease.
Although the valine change had no observable effects during simu-
lation, the A1135E mutation signiﬁcantly disrupted the active site
stability. The human INSR(A1135E) has previously been shown to
have processing defects in the endoplasmic reticulum (ER),
preventing .95% of the receptor from reaching the cell surface
(Cama et al. 1993). Our simulation demonstrated that any INSR
(A1135E) making it to the cell surface would likely be compromised
for function, based on a very unstable kinase active site.
n Table 3 Phenotypic consequences of human INSR and corresponding C. elegans DAF-2 mutations
The human INSR residue change (INSR D), associated human disorder, worm DAF-2 residue change (DAF-2 D), worm allele name (Allele), associated worm
phenotype, and class as deﬁned in (Gems et al. 1998; Patel et al. 2008) are shown. Residue numbering refers to the preproreceptor. NC, nonconditional Daf-c;
WT, wild-type; ?, unknown; DS, Donohue Syndrome; RMS, Rabson-Mendenhall Syndrome. Colors as described in Figure 3.
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DISCUSSION
An emerging spectrum of human
insulin receptoropathies
Over 150 different alleles have already been described in the human
insulin receptor; this list is likely to expand greatly in the near future
owing to the ever-decreasing cost of acquiring genome sequence in-
formation, and themanyeffortsworld-wide incollecting large cohortsof
sequenced genomes. A key challenge for the medical research commu-
nity is to identify those alleles that are associated with disease risk, and
tailoring individual therapy for the best patient outcome.
Like many conserved pathways, dysfunction of IIS can result in a
range of diseasephenotypesdependingon thenature of the lesion.Thus,
the phenotypic consequences of INSR variants are graded from none to
very severe, reﬂecting the extent towhich signaling is compromised. It is
generally accepted that INSR polymorphisms retaining.50% receptor
function do not result in human disease (Kadowaki et al. 1988; Taylor
et al. 1992; Semple et al. 2011, 2016; Semple 2016). However, available
studies suggest that reduction of INSR function to the25–50% range
results in Type A Insulin Resistance (TA-IR), in which patients
present with hyperinsulinemia, acanthosis nigricans, polycystic
ovarian syndrome (PCOS), hirsuitism, and hyperandrogenism. Pa-
tients with ,25% INSR function have the more severe disorders
Rabson Mendenhall syndrome (RMS) and Donohue syndrome (DS;
formerly “leprechaunism”). Patients with RMS and DS have addi-
tional symptoms of linear growth retardation, impaired development
of skeletal muscle and adipose tissue, hypertrichosis, and additional
dysmorphic features. While patients with TA-IR have normal life-
spans, RMS and DS patients have a much worse prognosis, typically
living 3–17 yr for RMS, and ,3 yr for DS. These clinical outcomes
underscore the importance of fully understanding the functional
consequences of INSR mutations.
C. elegans as a model for insulin-like signaling
Thewormhas proven to be a genetically amenablemodel for examining
conserved biological pathways, such as the insulin-signaling pathway,
which is deregulated inmany human diseases.Wormgenetics provided
an early framework for understanding the order of this complex
signaling cascade. We developed the pipeline shown in Figure 1 to
determine ifC. elegans genetic tools could (1) improve our understand-
ing of the well-studied insulin-like receptor DAF-2, and (2) prove use-
ful for the analysis of human metabolic disease for which sequence
polymorphisms were readily available from exon-sequencing efforts.
Using a positive selection screen for daf-2mutants, David Gems’ group
has investigated the molecular basis of the different alleles resulting in a
dauer-associated phenotype. Their analysis resulted in the clustering of
existent genetic alleles into two classes (I and II). Furthermore, they
developed an online tool (RILM) that contains a sequence alignment
acrossmany species, allowing them to note that the two Class I mutants
daf-2(m577) and daf-2(m596) occur at residues with known human
insulin receptor disease-causing mutations, both of which are thought
to cause processing defects. Here, we show numerous other Class II
daf-2 mutants that also occur in known human disease-causing resi-
dues (Table 3). While class distinction has proven useful for the more
severe Daf-c causing mutations, this distinction has not been made for
the weaker high-temperature induction of dauer (Hid) mutants pre-
sented in this study. Our results demonstrate that some human disease-
associated allele mimics in DAF-2 present with weaker phenotypes,
highlighting the importance of the biological assay and its sensitivity
in interpreting function.
Our study also tested the utility of the MMP resource in providing
new insights into the highly conserved and well-studied IIS pathway.
Phenotyping 40 daf-2MMP alleles using a relatively simple and quick
high temperature-induced dauer assay, we identify ﬁve new dauer al-
leles, and 35 tolerated DAF-2 substitutions (Table 1). We found that
accurately predicting phenotypes for animals harboring even severe
amino acid substitutions (e.g., charge reversal) was not possible, with
many nonconservative changes resulting in no phenotype, whereas
even conservative changes could lead to dauer phenotypes. Our study
expands the regions of DAF-2 explored by mutagenesis for functional
consequences, while revealing clear parallels to human disease alleles in
the evolutionarily conserved IIS pathway.
Human disease alleles in the conserved INSR receptor
are effectively modeled in C. elegans
One of the twice-backcrossed MMP daf-2 alleles lacking a Hid pheno-
type [gk169915, DAF-2(A1391T)] aligns with known human disease
alleles at the corresponding position in INSR (A1135V in a complex
heterozygote; A1135E in a heterozygote) (Cama et al. 1993; Moreira et al.
2010). The absence of a Hid phenotype in C. elegans for DAF-2(A1391T),
which we conﬁrmed by genomic editing in an otherwise wild-type
background, is surprising because of the change in charge for this
conserved residue within the tyrosine kinase domain that is predicted
to be more deleterious than the A to V change previously associated
with human disease. Our genetic results, coupled with the observation
that the alanine to threonine change is present in 10% of the 90 human
tyrosine kinase domains we inspected (File S6), suggests it may sim-
ilarly be a tolerated change in the human INSR (Manning et al. 2002).
Further analysis of this alanine1391 residue demonstrated our ability
to leverage the relatively quick genomic editing in C. elegans to model
multiple alleles associated with human disease at the corresponding
position in INSR. In fact, the edited substitutions in C. elegans gen-
erate an allelic series of phenotypic severity, matching, and further
clarifying, that observed in human patients.
The human A to V1135 INSR mutation has only been observed as
one of the components of a compound heterozygous mutation: INSR
(N851S; A1135V). As RMS is seen only with either homozygous INSR
mutations or compound heterozygous mutations, it can be assumed
n Table 4 Genomic edits conﬁrming an MMP allele and modeling a human allelic series at the conserved residue INSR(A1135)
CRISPR-Cas9 was used to alter DAF-2(A1391) to the indicated residues and the results are shown for dauer assays performed at indicated temperatures. As observed
with human INSR(A1135) mutations, these alteration result in a graded range of phenotypes, from no observable phenotype to constitutive dauer formation at all
tested temperatures. N.D., not determined. Numbering refers to the preproreceptor. Color as described in Figure 3.
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that both mutations cause a signiﬁcant loss of function. However, the
degree of loss of function due to each allele is still unknown. The A to E
substitution at the same residue has already been shown in cell culture
to cause misfolding of the protein in the ER, resulting in only a small
fraction of this protein reaching the plasma membrane to interact with
ATP (Cama et al. 1993). Whether the A to V substitution causes a
similar effect is unknown. Notably, the A to T1135 INSR mutation has
not yet been observed in humans, even though 10% of human tyrosine
kinases have a threonine at this position. Our results in C. elegans have
demonstrated that these three substitutions constitute an allelic series,
strongly suggesting that human disease severity results from an analo-
gous graded effect of these changes on INSR function.
The available crystal structures of human tyrosine kinases and mo-
lecular dynamics simulations provide an approach to understanding how
mutations may induce graded effects on tyrosine kinase function (Table
S7). By replacing the A1135 INSR residue with a threonine, the 3.0 Å
distance between the substituted threonine’s hydroxyl group and the
carboxylic acid group of E1201 suggested a potential hydrogen bond
stabilizing the two charged residues in a relatively otherwise hydrophobic
pocket of the protein. In the 10% of human tyrosine kinases normally
containing a threonine corresponding to the A1135 INSR residue, a
hydrogen bond can be seen in seven crystal structures, providing further
support for the INSR hydrogen bond explanation for how the threonine
replacement could occur without signiﬁcantly altering the stability of the
protein. CHARMM molecular dynamics simulations of all three mis-
sensemutations in the human INSR conﬁrmed the T1135–E1201 hydrogen
bond and demonstrated that the A to T and A to V changes retained
active site stability, while the A to E change did not (videos in File S2, File
S3, File S4, and File S5). Thus, analysis and modeling of these three
substitutions provides an explanation for the genetic results observed
in C. elegans, and the degree of disease severity in humans.
Misfolding of the INSR in the ER has been shown in humans to
mediatemany of the loss-of-functionmutations (Taylor 1992). It would
be interesting to directly address DAF-2(A1391E) protein folding, traf-
ﬁcking, and membrane localization; however, suitable reagents for
these type of experiments have yet to be developed in C. elegans. Aug-
menting the facile genetics of the worm system with in vivoDAF-2 cell
biology will greatly advance our understanding the molecular mecha-
nisms of dysfunction and add another dimension to modeling human
INSR disease alleles.
Residue conservation predicts phenotypic
consequences for mutations
The MMP resource allows us to address the question of whether past
phenotypic selections biased our collection of mutants affecting DAF-2
function. It did not; mutations in highly conserved residues are very
likely to have phenotypic consequence. Five previously identiﬁed ge-
netic alleles resulting in dauer formation defects in C. elegans result
from substitutions in residues conserved in human INSR; our current
study adds another two to the list (Table 3).
Changes to evolutionarily constrained residues in the insulin-like
receptor DAF-2 have phenotypic consequences in C. elegans that cor-
relate well with disease severity in humans with corresponding alter-
ations. Of the ﬁve previously identiﬁed genetic reduction-of-function
alleles in daf-2, each alters an amino acid residue that is identical to
either 27/27 or 26/27 related receptors from multiple species that we
aligned. The classic daf-2(e1370) allele encodes DAF-2(P1465S) that
aligns with the INSR(P1209A) mutation in a patient with Type A
Insulin Resistance (TA IR); this proline residue is on the aF-helix
of the tyrosine kinase domain. The daf-2(e1391) allele encodes
DAF-2(P1434S) that aligns with the INSR(P1178L) mutation located
in the middle of the activation segment of the tyrosine kinase domain
and is commonly mutated in patients with TA IR. The daf-2(sa223)
allele encodes DAF-2(R1430Q) that perfectly matches the INSR
(R1174Q) amino acid change found in seven patients with TA IR.
The daf-2(m579) allele encodes DAF-2(R437C) that perfectly matches
a patient with TA IR with an INSR(R252C) mutation and aligns with
the INSR(R252H) mutation in another patient with TA IR. This argi-
nine is in the insulin-binding domain immediately adjacent to a com-
pletely conserved cysteine that likely plays a role in folding and may
participate in an intrachain disulﬁde bond. The daf-2(m596) allele
encodes DAF-2(G547S) that aligns with a compound heterozygous
patient with INSR(G366R; V28A) mutations resulting in DS—the
most severe form of human insulin resistance. Of the aligned recep-
tors, this glycine is conserved in the insulin binding domains of
human, chimp, mouse, rat, frog, and zebraﬁsh, and ﬁve out of six
of the Caenorhabditids (C. briggsae had a glutamate at this residue).
Thus, the most highly conserved domains of the INSR and DAF-2
are functionally dependent on the primary amino acid sequence,
and substitutions have a high likelihood of resulting in dysfunction;
a similar conclusion was reached by (Ng and Henikoff 2006).
Our current results using the MMP resource further support these
conclusions, but also reveal at least one major surprise. Most of the
DAF-2 substitutions we assayed for a Hid phenotype, a single yet
sensitive metric for function, were wild type and in nonconserved
residues. Therefore, the large majority of alleles following mutagenesis
and selection only for viability have no obvious deleterious effect on
DAF-2 function. As described above, one of these (DAF-2(A1391T))
was, nonetheless, very informative in suggesting a functionally tolerated
change that is unlikely to result in human disease if identiﬁed in INSRs.
Figure 5 Conserved and divergent domains of
four insulin-like preproreceptors. Protein sche-
matics were drawn to scale relative to the number
of amino acids in each domain. The worm DAF-2
domains were mapped onto the other receptors
using anchored T-COFFEE alignment (File S1).
The Fly InR C-terminus contains multiple
NPXYXXM motifs, which can bind both IRS-like
proteins and PI3K (Poltilove et al. 2000). The Human
IGF1 “dependence receptor” has a proapoptotic
C-terminus (skull and crossbones) (O’Connor et al.
1997; Hongo et al. 1998; Liu et al. 1998;
Goldschneider and Mehlen 2010). Unless indi-
cated otherwise, domain designations are as
shown in Figure 3.
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The threeMMP alleles that did result in a Hid phenotype identify novel
residues in which alterations would be predicted to have functional
consequences for the human INSR, and have a high likelihood of being
associated with human disease; we would expect disease severity to
correspond to the strength of the Hid phenotype in C. elegans.
Novel genetic insight into the C-terminal domain
of DAF-2
One of the dauer-enhancingMMP alleles, DAF-2(A1729V), conﬁrmed
by CRISPR-Cas9 genome editing, is located in the C-terminal domain,
a stretch of 658 amino acids lacking previous genetic hits. Although
present in all INSR-related receptors, the C-terminal domain of the
protein displays little to no conservation in its amino acid sequence
or its length (Figure 5). The human IGF-1 receptor has previously been
shown to act as a dependence receptor, with the release of proapoptotic
peptide cleavage products of the C-terminal domain during an absence
of growth factor signaling (O’Connor et al. 1997; Hongo et al. 1998; Liu
et al. 1998; Goldschneider and Mehlen 2010). In ﬂies, the C-terminal
domain of InR has the properties of Insulin Receptor Substrate proteins
(IRSs) that, in humans, are encoded by four distinct genes (Poltilove
et al. 2000). Fusion of the intracellular domains of the Drosophila InR
protein to the human INSR ectodomain rescues the loss of INSR sig-
naling in a mammalian cell line lacking all four human IRS proteins.
Interestingly, knockout of the sole ﬂy ortholog of IRSs, Chico, results in
a completely different nonlethal phenotype than the InR knockout in
ﬂies. Therefore, while the C-terminal domain of InR in Drosophila can
substitute functionally for absent human IRS proteins in tissue culture
systems, theremay be additional in vivo functions of this domain in ﬂies
that are unrelated to canonical IIS.
Results fromDrosophilamay be relevant to understanding a role for
the C. elegans DAF-2 C-terminal domain. DAF-2 and ﬂy InR share
many characteristics, including being the sole insulin-like receptor, and
both possess a long C-terminal domain with numerous tyrosine resi-
dues (Figure 5). Like ﬂies,C. elegans has a single ortholog of IRSs, IST-1.
Mutations in ist-1 can enhance the dauer phenotype, but only when
combined with daf-2 loss-of-function mutations (Wolkow et al. 2002),
suggesting that IST-1, like Chico in ﬂies, is not essential for signaling
through the IIS pathway. Thus, it seems plausible that the wormmight
share yet another feature with the ﬂy: the ability to signal directly
through the C-terminal domain instead of requiring recruitment of
IRS proteins to the plasma membrane. Our characterization of a weak
dauer-enhancing MMP allele that results in DAF-2(A1729V) demon-
strates for the ﬁrst time that the C-terminal domain is required for
proper IIS signaling.
Summary
In this study, insulin-like receptor signaling was interrogated by char-
acterizing a rich array of novel C. elegans mutations, making compar-
isons to known human disease-causing insulin receptor alleles, and
using whole animal in vivo functional assays of allele variants. Capital-
izing on the strengths of the worm system, including forward genetics,
existing deﬁned gene alleles, and relatively easy genomic editing by
CRISPR-Cas9, we were able to quickly phenotype 40 novel alleles, while
also creating and assaying human allele mimics. Our results were a mix
of the expected and unexpected, highlighting the importance of testing
allele function in the context of a whole animal system in which re-
ceptor processing and function are integrated with the entire metabolic
program. Our experiences with the insulin-like signaling pathway in
C. elegans demonstrates the power of this model system to better un-
derstand the possible organismal-level consequence of mutations in
conserved physiological processes. Facile CRISPR-Cas9 genomic edit-
ing makes feasible the assessment of any suitable human allele sus-
pected of disrupting gene function in a model system for which a
robust assay exists or can be developed. This opens new possibilities
for interpreting the increasing volumes of human genome sequence
data for identify mutations contributing to human diseases.
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